#USA #San Diego #Aethlon Medical #Hemopurifier #Long COVID

Aethlon Medical's Groundbreaking Research in Long COVID

Aethlon Medical, Inc., a prominent name in medical therapeutics, recently announced significant findings related to Long COVID, showcasing a promising biomarker and potential therapeutic target through their Hemopurifier® device. This development emerges from a peer-reviewed study published in the
International Journal of Molecular Sciences, which provides a substantial basis for the company's innovative approach to combating Long COVID.

Understanding Long COVID and Its Challenges

Long COVID presents an array of persistent symptoms that affect individuals long after the acute phase of COVID-19 has resolved. This condition remains a critical area of focus for healthcare professionals and researchers, as understanding its biological underpinnings could pave the way for effective treatments. Aethlon's study highlights the role of extracellular vesicles (EVs), specifically mannosylated EVs, as pivotal indicators of this condition.

Key Findings from the Study

The research implemented advanced techniques to analyze plasma samples from participants involved in the Long-term Impact of Infection with Novel Coronavirus (LIINC) study at the University of California, San Francisco (UCSF). Among the study's findings:

• - Elevated EV Levels: Patients grappling with Long COVID showed a remarkable increase—approximately two-fold—of mannose-positive extracellular vesicles compared to individuals who fully recovered from COVID-19.
• - Effective Capture Using Hemopurifier: The Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Hemopurifier proved effective in capturing these disease-associated glycosylation patterns from small EVs.
• - Reduced MicroRNA Levels: Treatment with GNA affinity resin resulted in a significant drop in seven circulating microRNAs that influence immune responses and inflammatory pathways.
• - Biological Pathway Insights: The study's computational pathway analysis pointed to modulation in critical pathways noted in Long COVID, including JAK-STAT, VEGF, and PI3K.

According to Jim Frakes, CEO and CFO of Aethlon Medical, these findings bolster the understanding of Long COVID's biological mechanisms and enhance the rationale for evaluating the Hemopurifier in addressing this medical need. Frakes emphasized that while their current focus is on advancing oncology trials in Australia, the potential applications of the Hemopurifier extend beyond just cancer treatment.

The Hemopurifier®: A Multifunctional Therapeutic Device

The Hemopurifier represents a groundbreaking approach in medical technology, aimed at removing life-threatening viruses and harmful EVs from the bloodstream. The FDA has recognized it as a Breakthrough Device, indicating its potential benefits in treating patients with advanced cancers and severe virus infections. With the added insights gained from this recent study, Aethlon plans to explore the device's utility further in combating Long COVID, thus potentially addressing a significant healthcare challenge.

The study titled “Increased Mannosylation of Extracellular Vesicles in Long COVID Plasma as a Binding Target for Galanthus nivalis Agglutinin (GNA) Affinity Resin” can be accessed in full at the International Journal of Molecular Sciences.

Future Directions and Considerations

While Aethlon Medical continues to focus on its primary clinical trials, the findings from this research underscore the excitement surrounding the Hemopurifier's capabilities. There exists a notion of a ‘pipeline within a single device,’ hinting at its versatility across multiple disease areas. The company remains committed to evaluating the Hemopurifier's role in fulfilling an unmet need for patients suffering from Long COVID and potentially altering the landscape of treatment options available for this debilitating condition.

For more information about Aethlon Medical and their innovative approaches, visit AethlonMedical.com.

• ---

This article reflects a snapshot of vital medical advancements undertaken by Aethlon Medical regarding Long COVID and emphasizes the ongoing efforts in research and development within the healthcare sector.